| Drug ID: | Drug155 |
|---|---|
| Drug Name: | TOP1288 |
| CID: | 81689783 |
| DrugBank ID: | DB14839 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT02888379, , NCT02463045, , NCT03071081 |
| Molecular Formula: | C43H49N7O9S |
| Molecular Weight: | 840.0 g/mol |
| Isomeric SMILES: | CC(C)(C)C1=CC(=C(C(=C1)NS(=O)(=O)C)OC)NC(=O)NC2=CC=C(C3=CC=CC=C32)OC4=NC(=NC=C4)NC5=CC(=CC(=C5)C(=O)NCCOCCOCCOC)C#C |
| Synonyms: | TOP-1288; TOP1288; 19ZTZ9YC4O; UNII-19ZTZ9YC4O; 1630202-02-6; Benzamide, 3-((4-((4-((((5-(1,1-dimethylethyl)-2-methoxy-3-((methylsulfonyl)amino)phenyl)amino)carbonyl)amino)-1-naphthalenyl)oxy)-2-pyrimidinyl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-; 3-((4-((4-(((5-tert-butyl-3-methanesulfonamido-2-methoxyphenyl)carbamoyl)amino)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide; 3-({4-[(4-{[(5-tert-butyl-3-methanesulfonamido-2-methoxyphenyl)carbamoyl]amino}naphthalen-1-yl)oxy]pyrimidin-2-yl}amino)-5-ethynyl-N-{2-[2-(2-methoxyethoxy)ethoxy]ethyl}benzamide; CHEMBL3681949; SCHEMBL16106446 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02463045 | Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects | PHASE1 | COMPLETED | Topivert Pharma Ltd | Ulcerative Colitis | DRUG: TOP1288 | Details |
| NCT03071081 | Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects | PHASE1 | COMPLETED | Topivert Pharma Ltd | Ulcerative Colitis | DRUG: TOP1288|DRUG: Placebo to TOP1288 | Details |
| NCT02888379 | Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis | PHASE2 | COMPLETED | Topivert Pharma Ltd | Ulcerative Colitis | DRUG: TOP1288|DRUG: Placebo (for TOP1288) | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations